PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

NNIT wins five-year international infrastructure outsourcing agreement with global life science company

NNIT, a leading provider of IT services and consultancy, announces that it has signed its first global infrastructure outsourcing agreement within the international life science industry segment.
 
The agreement covers global services including support and maintenance of the global IT infrastructure for Lonza, one of the world’s leading and most-trusted pharmaceutical, biotech and specialty ingredients markets’ suppliers.
 
“Signing with Lonza marks an important milestone in NNIT’s vision of becoming a trusted provider of regulated IT for life sciences worldwide,” says Per Kogut, CEO at NNIT. He continues: “We are proud to outmatch major IT-infrastructure outsourcing competitors and realizing our strategic ambition.”
 
Lonza has more than 50 major manufacturing and R&D facilities and 14,000 full-time employees worldwide across 90 sites in 30 countries. Following the closing of the Capsugel acquisition, Lonza further strengthened its position as one of the world’s leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. 
 
“In NNIT we have found a partner with a strong legacy in life sciences who acknowledges the requirements for critical infrastructure and understands what it takes to comply. We are particularly impressed with NNIT’s GxP validated setup and the full stack of services,” explains Ernst Hutter, Head of Corporate IT Infrastructure Services at Lonza.
 
The infrastructure outsourcing agreement covers remote management of two datacentres in Switzerland, and Lonza has the option to gradually move to NNIT datacentres when procuring new services. Furthermore, NNIT will manage all remote LAN and servers & storage globally, including 13 production sites with GxP (good Quality Practice guidelines) requirements.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026